WO2010024702A3 - Pharmaceutical composition for the treatment of periodontal diseases - Google Patents

Pharmaceutical composition for the treatment of periodontal diseases Download PDF

Info

Publication number
WO2010024702A3
WO2010024702A3 PCT/PL2009/050024 PL2009050024W WO2010024702A3 WO 2010024702 A3 WO2010024702 A3 WO 2010024702A3 PL 2009050024 W PL2009050024 W PL 2009050024W WO 2010024702 A3 WO2010024702 A3 WO 2010024702A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
mass
treatment
human
well
Prior art date
Application number
PCT/PL2009/050024
Other languages
French (fr)
Other versions
WO2010024702A2 (en
Inventor
Maciej Siewinski
Jan Wnukiewicz
Beata Wnukiewicz
Katarzyna Malolepsza-Jarmolowska
Jan Nienartowicz
Tadeusz Sebzda
Marek Bryjak
Tadeusz Trziszka
Original Assignee
Akademia Medyczna Im. Piastow Slaskich We Wroclawiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akademia Medyczna Im. Piastow Slaskich We Wroclawiu filed Critical Akademia Medyczna Im. Piastow Slaskich We Wroclawiu
Priority to EP09737192A priority Critical patent/EP2349199A2/en
Publication of WO2010024702A2 publication Critical patent/WO2010024702A2/en
Publication of WO2010024702A3 publication Critical patent/WO2010024702A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Abstract

A pharmaceutical composition for the treatment of periodontitis. A pharmaceutical composition according to the present invention is in the form of a gel with a selected viscosity. Its active ingredient is a base comprising a cysteine protease inhibitor from egg protein, urine, human or animal amniotic fluid, human or animal placentae as well as plants, with an activity of 1 - 50 inhibition units, suspended in 50 g of a polyhydroxyl alcohol and 50 g of a 0.05 molar phosphate buffer solution at a p H of 6.0 to 7.5, from 20 to 50 % by mass, whereas its carrier comprises gelling substances, from 7 to 20 % by mass, as well as water to 100% by mass. The gelling substances may be methylcellulose, hydroxypropylmethyl-cellulose, carboxymethylcellulose sodium salt, gelatin, apple-citrus pectin or a dextran. Preferentially, additives in the form of polyhydroxyl alcohols and Nipagin are used.
PCT/PL2009/050024 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases WO2010024702A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09737192A EP2349199A2 (en) 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL385972A PL219098B1 (en) 2008-08-28 2008-08-28 Pharmaceutical composition for therapy of parodonthium deseases
PLPL385972 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010024702A2 WO2010024702A2 (en) 2010-03-04
WO2010024702A3 true WO2010024702A3 (en) 2011-06-03

Family

ID=41343718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2009/050024 WO2010024702A2 (en) 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases

Country Status (3)

Country Link
EP (1) EP2349199A2 (en)
PL (1) PL219098B1 (en)
WO (1) WO2010024702A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113037A1 (en) * 2011-02-25 2012-08-30 The University Of Melbourne Method for inhibiting proteins
RU2606040C2 (en) * 2015-04-01 2017-01-10 Ирина Николаевна Усманова Method for treating chronic inflammation of paradentium tissues and mucous membrane with hyperkeratosis in young individuals
RU2637413C1 (en) * 2016-07-04 2017-12-04 Ирина Николаевна Усманова Method for treatment of oral mucosa chronic inflammation with hyperkeratosis elements in young persons
PL239917B1 (en) * 2018-11-28 2022-01-24 Univ Medyczny Im Piastow Slaskich We Wroclawiu Implantological composition containing cystatin and its composition in bone implantology
WO2020167152A1 (en) * 2019-02-15 2020-08-20 RAPAK, Andrzej Marek Inhibitors of cysteine peptidases isolated from natural raw materials and use of the inhibitors in medicine and veterinary medicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206963A1 (en) * 1999-03-30 2003-11-06 Yukihiro Takada Bone resorption suppressing agent
PL190404B1 (en) * 1999-08-02 2005-12-30 Akad Medyczna Pharmacological agent effectively acting against neoplasms, pathogenic micro-organisms and invasive diseases
US20070053849A1 (en) * 2000-06-30 2007-03-08 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
PL195665B1 (en) * 2000-06-13 2007-10-31 Przed Farmaceutyczne Jelfa Sa Pharmacological agent for local application in treating parodontium diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206963A1 (en) * 1999-03-30 2003-11-06 Yukihiro Takada Bone resorption suppressing agent
PL190404B1 (en) * 1999-08-02 2005-12-30 Akad Medyczna Pharmacological agent effectively acting against neoplasms, pathogenic micro-organisms and invasive diseases
PL195665B1 (en) * 2000-06-13 2007-10-31 Przed Farmaceutyczne Jelfa Sa Pharmacological agent for local application in treating parodontium diseases
US20070053849A1 (en) * 2000-06-30 2007-03-08 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents

Also Published As

Publication number Publication date
PL385972A1 (en) 2010-03-01
WO2010024702A2 (en) 2010-03-04
EP2349199A2 (en) 2011-08-03
PL219098B1 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
HRP20090340T1 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
WO2010024702A3 (en) Pharmaceutical composition for the treatment of periodontal diseases
RS51213B (en) Pharmacetical vaginal gel comprising tenofovir
BR0312975A (en) Crystalline form of ß2 adrenergic receptor agonist
MX336114B (en) Production, formulation, and uses of stable liquid harpin protein formulations.
EA201270201A1 (en) STICKY SOFT GEL FOR PROCESSING PETS
TR200801337T1 (en) Compositions containing poorly water soluble pharmaceutical agents and antimicrobial agents.
BRPI0509214A (en) compound, composition, and methods of inhibiting histone deacetylase in a cell, and of treating a cell proliferative condition or disease in an animal
BR0215517A (en) Antiseptic composition, and methods for disinfecting tissue and for producing an antiseptic composition
DE602006017057D1 (en) DEHYDRACETIC ACID COMPOSITIONS WITH LOW PH
ES2531083T3 (en) Stable polypeptide formulations and uses thereof
EA200970296A1 (en) CONTAINING DIARYL ETHER OF UREA COMPOUNDS
FR2916356B1 (en) NOVEL AGENT FOR RELOCATING ACTIVE INGREDIENTS IN DRESSINGS CONTAINING AT LEAST ONE FATTY BODY
MX2010014233A (en) Chemical compounds 251.
PT1119362E (en) METHODS FOR THE USE OF TETRACYCLINE COMPOUNDS TO INCREASE THE PRODUCTION OF INTERLEUCIN-10
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
NZ590218A (en) Fungicidal composition and method for controlling plant diseases
BR0316629A (en) Substituted urea and carbamates
FR2978047B1 (en) NEW HEMOSTATIC COMPOSITION
ES2720954T3 (en) Statin Stabilized Formulations
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
UA95224C2 (en) Anti-acid pharmaceutical composition in powder form and process for making it
RU2013112667A (en) COMPOSITION FOR CARE OF THE ORAL CAVITY AND METHOD FOR PRODUCING AND USE
AR064262A1 (en) LIQUID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMPOSITE BISFOSFONATO
ATE473752T1 (en) USE OF COMPOUNDS FOR INDUCING THE SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PRODUCTION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737192

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009737192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009737192

Country of ref document: EP